588
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

      research-article
      , Prof, FRCP a , * , , PhD a , , RN b , , Prof, MD c , d , , MD e , , BSc f , , MD g , , Prof, FRCPath h , , PhD h , i , , PhD b , , MD j , , MD k , , MBBS l , , MD m , , Prof, PhD n , , MD o , , Prof, MD p , , MD q , , Prof, MD r , , MD s , , MD t , , Prof, PhD u , , Prof, MD v , , MD w , , Prof, MD x , , Prof, PhD y , , Prof, PhD z , , MD aa , , Prof, MedScD ab , , PhD ac , , PhD ad , , MD ae , , Prof, MedScD af , , Prof, PhD a , , Prof, PhD b , PARTNER Study Group
      Lancet (London, England)
      Elsevier

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background

          The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.

          Methods

          The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods.

          Findings

          Between Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1–3·5). At baseline, median age for HIV-positive partners was 40 years (IQR 33–46) and couples reported condomless sex for a median of 1·0 years (IQR 0·4–2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up).

          Interpretation

          Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV.

          Funding

          National Institute for Health Research.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Prevention of HIV-1 infection with early antiretroviral therapy.

          Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. In nine countries, we enrolled 1763 couples in which one partner was HIV-1-positive and the other was HIV-1-negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1-infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1-related symptoms (delayed therapy). The primary prevention end point was linked HIV-1 transmission in HIV-1-negative partners. The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P<0.001). Subjects receiving early therapy had fewer treatment end points (hazard ratio, 0.59; 95% CI, 0.40 to 0.88; P=0.01). The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 052 ClinicalTrials.gov number, NCT00074581.).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

            A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral therapy (ART) as a prevention strategy is the absolute risk of HIV transmission through condomless sex with suppressed HIV-1 RNA viral load for both anal and vaginal sex.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1

              We examined the influence of viral load in relation to other risk factors for the heterosexual transmission of human immunodeficiency virus type 1 (HIV-1). In a community-based study of 15,127 persons in a rural district of Uganda, we identified 415 couples in which one partner was HIV-1-positive and one was initially HIV-1-negative and followed them prospectively for up to 30 months. The incidence of HIV-1 infection per 100 person-years among the initially seronegative partners was examined in relation to behavioral and biologic variables. The male partner was HIV-1-positive in 228 couples, and the female partner was HIV-1-positive in 187 couples. Ninety of the 415 initially HIV-1-negative partners seroconverted (incidence, 11.8 per 100 person-years). The rate of male-to-female transmission was not significantly different from the rate of female-to-male transmission (12.0 per 100 person-years vs. 11.6 per 100 person-years). The incidence of seroconversion was highest among the partners who were 15 to 19 years of age (15.3 per 100 person-years). The incidence was 16.7 per 100 person-years among 137 uncircumcised male partners, whereas there were no seroconversions among the 50 circumcised male partners (P<0.001). The mean serum HIV-1 RNA level was significantly higher among HIV-1-positive subjects whose partners seroconverted than among those whose partners did not seroconvert (90,254 copies per milliliter vs. 38,029 copies per milliliter, P=0.01). There were no instances of transmission among the 51 subjects with serum HIV-1 RNA levels of less than 1500 copies per milliliter; there was a significant dose-response relation of increased transmission with increasing viral load. In multivariate analyses of log-transformed HIV-1 RNA levels, each log increment in the viral load was associated with a rate ratio of 2.45 for seroconversion (95 percent confidence interval, 1.85 to 3.26). The viral load is the chief predictor of the risk of heterosexual transmission of HIV-1, and transmission is rare among persons with levels of less than 1500 copies of HIV-1 RNA per milliliter.
                Bookmark

                Author and article information

                Contributors
                Journal
                Lancet
                Lancet
                Lancet (London, England)
                Elsevier
                0140-6736
                1474-547X
                15 June 2019
                15 June 2019
                : 393
                : 10189
                : 2428-2438
                Affiliations
                [a ]Institute for Global Health, University College London, London, UK
                [b ]Department of Infectious Diseases (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
                [c ]Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, St Gallen, Switzerland
                [d ]HIV i-Base, London, UK
                [e ]University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
                [f ]European AIDS Treatment Group, Brussels, Belgium
                [g ]Hospital Clinico San Carlos and Universidad Complutense, Madrid, Spain
                [h ]Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
                [i ]Department of Biomedical Sciences, University of West Attica, Athens, Greece
                [j ]AIDS Research Institute-IrsiCaixa, Hospital Universitari Germans Trias i Pujol and BCN Checkpoint, Badalona and Barcelona, Spain
                [k ]Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy
                [l ]Chelsea and Westminster NHS Foundation Trust, London, UK
                [m ]Medical University of Vienna, Vienna, Austria
                [n ]Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
                [o ]Venhälsan, Södersjukhuset, Stockholm, Sweden
                [p ]Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
                [q ]DC Klinieken, Amsterdam, Netherlands
                [r ]Centre for Sexual Health and Medicine, Walk in Ruhr, Ruhr University Bochum, Bochum, Germany
                [s ]Brighton and Sussex University Hospitals NHS Trust, and Brighton and Sussex Medical School, Brighton, UK
                [t ]Centro Sanitario Sandoval, Madrid, Spain
                [u ]Infectious Diseases Department, University Hospital (Centre Hospitalier Universitaire de Nantes) Hotel-Dieu, and INSERM UIC 1413 Nantes University, Nantes, France
                [v ]Medizinische Klinik und Poliklinik IV, University Hospital Munich, Munich, Germany
                [w ]Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland
                [x ]Rigshospitalet, Copenhagen, Denmark
                [y ]Hospital General de Elche and Universidad Miguel Hernández, Alicante, Spain
                [z ]Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands
                [aa ]Medical University Innsbruck, Innsbruck, Austria
                [ab ]Aarhus University Hospital, Skejby, Denmark
                [ac ]Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain
                [ad ]Helsinki University Hospital and University of Helsinki, Helsinki, Finland
                [ae ]Praxis Jessen 2 + Kollegen, Berlin, Germany
                [af ]ICH Study Centre, Hamburg, Germany
                Author notes
                [* ]Correspondence to: Prof Alison J Rodger, Institute for Global Health, University College London, London NW3 2PF, UK alison.rodger@ 123456ucl.ac.uk
                [†]

                PARTNER Study Group listed at the end of the paper

                Article
                S0140-6736(19)30418-0
                10.1016/S0140-6736(19)30418-0
                6584382
                31056293
                e1fd5d83-f97b-44fe-bf9b-c71b62343618
                © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                Medicine
                Medicine

                Comments

                Comment on this article